Ruijin Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

360

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

44 drugs in development

Phase 36

Phase 224

Phase 111

Preclinical10

By Therapeutic Area

top 6

Oncology

1834%

Immunology

48%

Hematology

36%

Neurology

24%

Metabolic & Endocrine

12%

Nephrology

12%

R&D Momentum

96/100

Pipeline Velocity

77/100

Trial Completion Rate

87/100

Pipeline Concentration

28/100

Pipeline Freshness

67/100

Strategic Signals

↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 18, 2026

Recruiting

Predicting Efficacy of Preoperative Immunotherapy Combined Treatment in Advanced Gastric Cancer

Sep 11, 2026

Recruiting

Screening for Urological Malignancies Using a Urine Exfoliated Cell Fluorescence Assay in a Hematuria Population: A Prospective Clinical Study

Sep 10, 2026

Completed

Individualized 130 Hz Subthalamic Temporal Interference Stimulation Versus Medication for Motor Symptoms in Parkinson Disease

Sep 9, 2026

Enrolling by invitation

A Prospective, National, Multicenter, Observational Real-World Study of Acalabrutinib in Chinese Patients With MCL/CLL/SLL(RESA)

Earlier

Sep 5, 2026TrialEarly Versus Deferred De-escalation From Controlled Ventilation After a 48-Hour Landmark of Physiological Stability

Sep 3, 2026Trial12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Tumors ≤1cm, Node-negative, HER2-positive Breast cancER (SOBER):a Single-grouparm, Open-label, Prospective, Phase 2 Study

Sep 3, 2026TrialA Single Center Pilot Trial of Preliminary Effect of Colchicine on Graft Failure in Patients Underwent CABG

Sep 3, 2026TrialMulticenter Prospective Cohort Study of Molecular Residual Disease (MRD) in Stage I-III Surgically Resectable Colon Adenocarcinoma Harboring Oncogenic Driver Mutations

1 more events

Sep 2, 2026TrialCorrelation Study on End-expiratory NO, H2S, H2, CH4, Intestinal Flora and Immune Function in Children With Constipation

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Hematology(3 drugs)

—

Hematology(3 drugs)

Immunology(4 drugs)

—

Immunology(4 drugs)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Metabolic & Endocrine(1 drug)

—

Metabolic & Endocrine(1 drug)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(2 drugs)

—

Neurology(2 drugs)

Oncology(18 drugs)

—

Oncology(18 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Unknown / Other(21 drugs)

—

Unknown / Other(21 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)